Mostrar el registro sencillo del ítem
Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease
dc.contributor.author | Górriz, José Luis | |
dc.contributor.author | Arroyo, David | |
dc.contributor.author | D'MARCO, LUIS | |
dc.contributor.author | Torra, Roser | |
dc.contributor.author | Tomás, Patricia | |
dc.contributor.author | Puchades, María Jesús | |
dc.contributor.author | Panizo, Nayara | |
dc.contributor.author | Pantoja, Jonay | |
dc.contributor.author | Montomoli, Marco | |
dc.contributor.author | Llisterri Caro, José Luis | |
dc.contributor.author | Pallarés-Carratalá, Vicente | |
dc.contributor.author | Valdivielso, José Manuel | |
dc.date.accessioned | 2021-06-02T08:09:16Z | |
dc.date.available | 2021-06-02T08:09:16Z | |
dc.date.issued | 2021-03-25 | |
dc.identifier.citation | Gorriz, J.L., Arroyo, D., D’Marco, L. et al. Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease. BMC Nephrol 22, 110 (2021). https://doi.org/10.1186/s12882-021-02313-1 | ca_CA |
dc.identifier.issn | 1471-2369 | |
dc.identifier.uri | http://hdl.handle.net/10234/193246 | |
dc.description.abstract | Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls. Methods: We evaluated 2445 CKD patients (2010–2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4 years. Results: ADPKD patients had a worse renal function and worst achievement of blood pressure, higher parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than half of the patients received statins, achieving LDL-c levels < 100 only in 50 and 39.8% of them (ADPKD and CKDoe respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221–0.808, p = 0.009). Conclusion: ADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be related with a lower load of CVD compared to other groups, which may lead in the long term to a better prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD. | ca_CA |
dc.format.extent | 10 p. | ca_CA |
dc.format.mimetype | application/pdf | ca_CA |
dc.language.iso | eng | ca_CA |
dc.relation.isPartOf | BMC nephrology, 2021, vol. 22 | ca_CA |
dc.rights | © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. | ca_CA |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-sa/4.0/ | * |
dc.subject | autosomal dominant polycystic kidney disease | ca_CA |
dc.subject | chronic kidney disease | ca_CA |
dc.subject | cardiovascular disease | ca_CA |
dc.subject | nephropathy | ca_CA |
dc.title | Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease | ca_CA |
dc.type | info:eu-repo/semantics/article | ca_CA |
dc.identifier.doi | https://doi.org/10.1186/s12882-021-02313-1 | |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca_CA |
dc.relation.publisherVersion | https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02313-1 | ca_CA |
dc.description.sponsorship | The NEFRONA study is funded by a research grant from AbbVie and the Spanish government RETIC (RD12/0021) and FIS PS10/00946. Torra R research is funded by the Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional (FEDER) funds, RETIC REDINREN RD16/0009 FIS FEDER FUNDS (PI15/01824, PI18/00362). | |
dc.type.version | info:eu-repo/semantics/publishedVersion | ca_CA |
project.funder.name | AbbVie | ca_CA |
project.funder.name | Spanish government | ca_CA |
project.funder.name | Instituto de Salud Carlos III | ca_CA |
project.funder.name | Fondo Europeo de Desarrollo Regional | ca_CA |
oaire.awardNumber | RETIC (RD12/0021) | ca_CA |
oaire.awardNumber | FIS PS10/00946 | ca_CA |
oaire.awardNumber | PI15/01824 | ca_CA |
oaire.awardNumber | PI18/00362 | ca_CA |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
MED_Articles [662]
Articles de publicacions periòdiques
Excepto si se señala otra cosa, la licencia del ítem se describe como: © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.